Finally, long-term adverse effects such as cardiovascular disease (which requires a dedicated cardiovascular outcome trial), bladder cancer (seen with some other peroxisome proliferator-activated receptor (PPAR) agonists), and liposarcomas (seen with muraglitazar) must be fully evaluated to ensure the long-term safety of saroglitazar in clinical practice [27,30,31,32,33]. The gene discussed is PPARA; the disease is urinary bladder carcinoma.